KICVentures Acquires Unique Portfolio of Synthetic Bioactive Glass for Its Newest Portfolio Company NanoFuse Biologics LLC

Monday, March 12, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

KICVentures acquires NanoFuse biologic platform, broadening its portfolio to serve new growth markets.

BOSTON, March 12, 2018 /PRNewswire-PRWeb/ -- KICVentures, a Boston-based private investment

firm leading in healthcare technology, announced today that it has acquired all assets of Amend Surgical Inc., offering several unique synthetic bioactive glass products and an FDA-cleared combination of demineralized bone matrix (DBM) and bioactive glass. The acquisition allows KICVentures to broaden its portfolio of biologics, positioning NanoFuse Biologics LLC to serve new markets and drive revenue growth worldwide. Amend Surgical Inc. will continue to manufacture the NanoFuseŽ Bioactive Matrix during the transition and focus exclusively on dental applications for the NanoFuse technology platform.

NanoFuse Bioactive Matrix is a unique and proprietary blend of DBM that combines the osteoinductive capabilities of demineralized bone with the osteostimulative properties of bioactive glass.

Results of animal studies conducted internally and by independent laboratories demonstrate that NanoFuse Bioactive Matrix performs better than other commercially available bone void ?ller implant preparations that include only DBM. Additionally, the calcium-based bioactive glass used in NanoFuse Bioactive Matrix allows production of an exceedingly strong interfacial bond between the graft and adjacent bony tissue within minutes.

"The NanoFuse matrix technology is the next generation of biologics, which, unlike any biologic on the market, offers surgeons the synergistic combination of bioactive glass and demineralized allograft bone in a single product," said KICVentures Founder and CEO, Orthopedic Surgeon Dr. Kingsley R. Chin. "The NanoFUSE matrix will come in a variety of configurations, offered as either a combination synthetic plus DBM or fully synthetic product - both of which KICVentures has the exclusive global rights to."

About KICVentures kicventures.com [KICVentures __title__ KICVentures] is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities, headquartered in Boston, Mass.

 

SOURCE KIC Ventures



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store